NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
Metrics to compare | ALNFL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALNFLPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.1x | −1.9x | −0.5x | |
PEG Ratio | −0.15 | 0.01 | 0.00 | |
Price/Book | - | 1.4x | 2.6x | |
Price / LTM Sales | 366,393.1x | 6.5x | 3.3x | |
Upside (Analyst Target) | 193.2% | 137.9% | 43.5% | |
Fair Value Upside | Unlock | 5.6% | 6.8% | Unlock |